Global Leiomyosarcoma Drug Market Growth 2025-2031

October 2025 | 96 pages | ID: GE9CC22DCD90EN
LP Information

Abstracts

The global Leiomyosarcoma Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the ?Leiomyosarcoma Drug Industry Forecast? looks at past sales and reviews total world Leiomyosarcoma Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Leiomyosarcoma Drug sales for 2025 through 2031. With Leiomyosarcoma Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Leiomyosarcoma Drug industry.

This Insight Report provides a comprehensive analysis of the global Leiomyosarcoma Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Leiomyosarcoma Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Leiomyosarcoma Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Leiomyosarcoma Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Leiomyosarcoma Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Leiomyosarcoma Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• AL-3818
• BGB-290
• C-21
• Others

Segmentation by Application:

• Clinic
• Hospital
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Advenchen Laboratories, LLC
• BeiGene, Ltd.
• Cell Medica Limited
• Karyopharm Therapeutics, Inc.
• Merck & Co., Inc.
• Mirati Therapeutics Inc.
• Novartis AG
• Vicore Pharma AB

Key Questions Addressed in this Report

What is the 10-year outlook for the global Leiomyosarcoma Drug market?
What factors are driving Leiomyosarcoma Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Leiomyosarcoma Drug market opportunities vary by end market size?
How does Leiomyosarcoma Drug break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Leiomyosarcoma Drug Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Leiomyosarcoma Drug by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Leiomyosarcoma Drug by Country/Region, 2020, 2024 & 2031
2.2 Leiomyosarcoma Drug Segment by Type
  2.2.1 AL-3818
  2.2.2 BGB-290
  2.2.3 C-21
  2.2.4 Others
2.3 Leiomyosarcoma Drug Sales by Type
  2.3.1 Global Leiomyosarcoma Drug Sales Market Share by Type (2020-2025)
  2.3.2 Global Leiomyosarcoma Drug Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Leiomyosarcoma Drug Sale Price by Type (2020-2025)
2.4 Leiomyosarcoma Drug Segment by Application
  2.4.1 Clinic
  2.4.2 Hospital
  2.4.3 Others
2.5 Leiomyosarcoma Drug Sales by Application
  2.5.1 Global Leiomyosarcoma Drug Sale Market Share by Application (2020-2025)
  2.5.2 Global Leiomyosarcoma Drug Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Leiomyosarcoma Drug Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Leiomyosarcoma Drug Breakdown Data by Company
  3.1.1 Global Leiomyosarcoma Drug Annual Sales by Company (2020-2025)
  3.1.2 Global Leiomyosarcoma Drug Sales Market Share by Company (2020-2025)
3.2 Global Leiomyosarcoma Drug Annual Revenue by Company (2020-2025)
  3.2.1 Global Leiomyosarcoma Drug Revenue by Company (2020-2025)
  3.2.2 Global Leiomyosarcoma Drug Revenue Market Share by Company (2020-2025)
3.3 Global Leiomyosarcoma Drug Sale Price by Company
3.4 Key Manufacturers Leiomyosarcoma Drug Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Leiomyosarcoma Drug Product Location Distribution
  3.4.2 Players Leiomyosarcoma Drug Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR LEIOMYOSARCOMA DRUG BY GEOGRAPHIC REGION

4.1 World Historic Leiomyosarcoma Drug Market Size by Geographic Region (2020-2025)
  4.1.1 Global Leiomyosarcoma Drug Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Leiomyosarcoma Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Leiomyosarcoma Drug Market Size by Country/Region (2020-2025)
  4.2.1 Global Leiomyosarcoma Drug Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Leiomyosarcoma Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Leiomyosarcoma Drug Sales Growth
4.4 APAC Leiomyosarcoma Drug Sales Growth
4.5 Europe Leiomyosarcoma Drug Sales Growth
4.6 Middle East & Africa Leiomyosarcoma Drug Sales Growth

5 AMERICAS

5.1 Americas Leiomyosarcoma Drug Sales by Country
  5.1.1 Americas Leiomyosarcoma Drug Sales by Country (2020-2025)
  5.1.2 Americas Leiomyosarcoma Drug Revenue by Country (2020-2025)
5.2 Americas Leiomyosarcoma Drug Sales by Type (2020-2025)
5.3 Americas Leiomyosarcoma Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Leiomyosarcoma Drug Sales by Region
  6.1.1 APAC Leiomyosarcoma Drug Sales by Region (2020-2025)
  6.1.2 APAC Leiomyosarcoma Drug Revenue by Region (2020-2025)
6.2 APAC Leiomyosarcoma Drug Sales by Type (2020-2025)
6.3 APAC Leiomyosarcoma Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Leiomyosarcoma Drug by Country
  7.1.1 Europe Leiomyosarcoma Drug Sales by Country (2020-2025)
  7.1.2 Europe Leiomyosarcoma Drug Revenue by Country (2020-2025)
7.2 Europe Leiomyosarcoma Drug Sales by Type (2020-2025)
7.3 Europe Leiomyosarcoma Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Leiomyosarcoma Drug by Country
  8.1.1 Middle East & Africa Leiomyosarcoma Drug Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Leiomyosarcoma Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Leiomyosarcoma Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Leiomyosarcoma Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Leiomyosarcoma Drug
10.3 Manufacturing Process Analysis of Leiomyosarcoma Drug
10.4 Industry Chain Structure of Leiomyosarcoma Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Leiomyosarcoma Drug Distributors
11.3 Leiomyosarcoma Drug Customer

12 WORLD FORECAST REVIEW FOR LEIOMYOSARCOMA DRUG BY GEOGRAPHIC REGION

12.1 Global Leiomyosarcoma Drug Market Size Forecast by Region
  12.1.1 Global Leiomyosarcoma Drug Forecast by Region (2026-2031)
  12.1.2 Global Leiomyosarcoma Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Leiomyosarcoma Drug Forecast by Type (2026-2031)
12.7 Global Leiomyosarcoma Drug Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Advenchen Laboratories, LLC
  13.1.1 Advenchen Laboratories, LLC Company Information
  13.1.2 Advenchen Laboratories, LLC Leiomyosarcoma Drug Product Portfolios and Specifications
  13.1.3 Advenchen Laboratories, LLC Leiomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Advenchen Laboratories, LLC Main Business Overview
  13.1.5 Advenchen Laboratories, LLC Latest Developments
13.2 BeiGene, Ltd.
  13.2.1 BeiGene, Ltd. Company Information
  13.2.2 BeiGene, Ltd. Leiomyosarcoma Drug Product Portfolios and Specifications
  13.2.3 BeiGene, Ltd. Leiomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 BeiGene, Ltd. Main Business Overview
  13.2.5 BeiGene, Ltd. Latest Developments
13.3 Cell Medica Limited
  13.3.1 Cell Medica Limited Company Information
  13.3.2 Cell Medica Limited Leiomyosarcoma Drug Product Portfolios and Specifications
  13.3.3 Cell Medica Limited Leiomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 Cell Medica Limited Main Business Overview
  13.3.5 Cell Medica Limited Latest Developments
13.4 Karyopharm Therapeutics, Inc.
  13.4.1 Karyopharm Therapeutics, Inc. Company Information
  13.4.2 Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Product Portfolios and Specifications
  13.4.3 Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Karyopharm Therapeutics, Inc. Main Business Overview
  13.4.5 Karyopharm Therapeutics, Inc. Latest Developments
13.5 Merck & Co., Inc.
  13.5.1 Merck & Co., Inc. Company Information
  13.5.2 Merck & Co., Inc. Leiomyosarcoma Drug Product Portfolios and Specifications
  13.5.3 Merck & Co., Inc. Leiomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Merck & Co., Inc. Main Business Overview
  13.5.5 Merck & Co., Inc. Latest Developments
13.6 Mirati Therapeutics Inc.
  13.6.1 Mirati Therapeutics Inc. Company Information
  13.6.2 Mirati Therapeutics Inc. Leiomyosarcoma Drug Product Portfolios and Specifications
  13.6.3 Mirati Therapeutics Inc. Leiomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 Mirati Therapeutics Inc. Main Business Overview
  13.6.5 Mirati Therapeutics Inc. Latest Developments
13.7 Novartis AG
  13.7.1 Novartis AG Company Information
  13.7.2 Novartis AG Leiomyosarcoma Drug Product Portfolios and Specifications
  13.7.3 Novartis AG Leiomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.7.4 Novartis AG Main Business Overview
  13.7.5 Novartis AG Latest Developments
13.8 Vicore Pharma AB
  13.8.1 Vicore Pharma AB Company Information
  13.8.2 Vicore Pharma AB Leiomyosarcoma Drug Product Portfolios and Specifications
  13.8.3 Vicore Pharma AB Leiomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.8.4 Vicore Pharma AB Main Business Overview
  13.8.5 Vicore Pharma AB Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Leiomyosarcoma Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Leiomyosarcoma Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of AL-3818
Table 4. Major Players of BGB-290
Table 5. Major Players of C-21
Table 6. Major Players of Others
Table 7. Global Leiomyosarcoma Drug Sales by Type (2020-2025) & (K Pcs)
Table 8. Global Leiomyosarcoma Drug Sales Market Share by Type (2020-2025)
Table 9. Global Leiomyosarcoma Drug Revenue by Type (2020-2025) & ($ million)
Table 10. Global Leiomyosarcoma Drug Revenue Market Share by Type (2020-2025)
Table 11. Global Leiomyosarcoma Drug Sale Price by Type (2020-2025) & (USD/Pcs)
Table 12. Global Leiomyosarcoma Drug Sale by Application (2020-2025) & (K Pcs)
Table 13. Global Leiomyosarcoma Drug Sale Market Share by Application (2020-2025)
Table 14. Global Leiomyosarcoma Drug Revenue by Application (2020-2025) & ($ million)
Table 15. Global Leiomyosarcoma Drug Revenue Market Share by Application (2020-2025)
Table 16. Global Leiomyosarcoma Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 17. Global Leiomyosarcoma Drug Sales by Company (2020-2025) & (K Pcs)
Table 18. Global Leiomyosarcoma Drug Sales Market Share by Company (2020-2025)
Table 19. Global Leiomyosarcoma Drug Revenue by Company (2020-2025) & ($ millions)
Table 20. Global Leiomyosarcoma Drug Revenue Market Share by Company (2020-2025)
Table 21. Global Leiomyosarcoma Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 22. Key Manufacturers Leiomyosarcoma Drug Producing Area Distribution and Sales Area
Table 23. Players Leiomyosarcoma Drug Products Offered
Table 24. Leiomyosarcoma Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Leiomyosarcoma Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 28. Global Leiomyosarcoma Drug Sales Market Share Geographic Region (2020-2025)
Table 29. Global Leiomyosarcoma Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 30. Global Leiomyosarcoma Drug Revenue Market Share by Geographic Region (2020-2025)
Table 31. Global Leiomyosarcoma Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 32. Global Leiomyosarcoma Drug Sales Market Share by Country/Region (2020-2025)
Table 33. Global Leiomyosarcoma Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 34. Global Leiomyosarcoma Drug Revenue Market Share by Country/Region (2020-2025)
Table 35. Americas Leiomyosarcoma Drug Sales by Country (2020-2025) & (K Pcs)
Table 36. Americas Leiomyosarcoma Drug Sales Market Share by Country (2020-2025)
Table 37. Americas Leiomyosarcoma Drug Revenue by Country (2020-2025) & ($ millions)
Table 38. Americas Leiomyosarcoma Drug Sales by Type (2020-2025) & (K Pcs)
Table 39. Americas Leiomyosarcoma Drug Sales by Application (2020-2025) & (K Pcs)
Table 40. APAC Leiomyosarcoma Drug Sales by Region (2020-2025) & (K Pcs)
Table 41. APAC Leiomyosarcoma Drug Sales Market Share by Region (2020-2025)
Table 42. APAC Leiomyosarcoma Drug Revenue by Region (2020-2025) & ($ millions)
Table 43. APAC Leiomyosarcoma Drug Sales by Type (2020-2025) & (K Pcs)
Table 44. APAC Leiomyosarcoma Drug Sales by Application (2020-2025) & (K Pcs)
Table 45. Europe Leiomyosarcoma Drug Sales by Country (2020-2025) & (K Pcs)
Table 46. Europe Leiomyosarcoma Drug Revenue by Country (2020-2025) & ($ millions)
Table 47. Europe Leiomyosarcoma Drug Sales by Type (2020-2025) & (K Pcs)
Table 48. Europe Leiomyosarcoma Drug Sales by Application (2020-2025) & (K Pcs)
Table 49. Middle East & Africa Leiomyosarcoma Drug Sales by Country (2020-2025) & (K Pcs)
Table 50. Middle East & Africa Leiomyosarcoma Drug Revenue Market Share by Country (2020-2025)
Table 51. Middle East & Africa Leiomyosarcoma Drug Sales by Type (2020-2025) & (K Pcs)
Table 52. Middle East & Africa Leiomyosarcoma Drug Sales by Application (2020-2025) & (K Pcs)
Table 53. Key Market Drivers & Growth Opportunities of Leiomyosarcoma Drug
Table 54. Key Market Challenges & Risks of Leiomyosarcoma Drug
Table 55. Key Industry Trends of Leiomyosarcoma Drug
Table 56. Leiomyosarcoma Drug Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Leiomyosarcoma Drug Distributors List
Table 59. Leiomyosarcoma Drug Customer List
Table 60. Global Leiomyosarcoma Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 61. Global Leiomyosarcoma Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 62. Americas Leiomyosarcoma Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 63. Americas Leiomyosarcoma Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 64. APAC Leiomyosarcoma Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 65. APAC Leiomyosarcoma Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 66. Europe Leiomyosarcoma Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 67. Europe Leiomyosarcoma Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Middle East & Africa Leiomyosarcoma Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 69. Middle East & Africa Leiomyosarcoma Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 70. Global Leiomyosarcoma Drug Sales Forecast by Type (2026-2031) & (K Pcs)
Table 71. Global Leiomyosarcoma Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 72. Global Leiomyosarcoma Drug Sales Forecast by Application (2026-2031) & (K Pcs)
Table 73. Global Leiomyosarcoma Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 74. Advenchen Laboratories, LLC Basic Information, Leiomyosarcoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 75. Advenchen Laboratories, LLC Leiomyosarcoma Drug Product Portfolios and Specifications
Table 76. Advenchen Laboratories, LLC Leiomyosarcoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 77. Advenchen Laboratories, LLC Main Business
Table 78. Advenchen Laboratories, LLC Latest Developments
Table 79. BeiGene, Ltd. Basic Information, Leiomyosarcoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 80. BeiGene, Ltd. Leiomyosarcoma Drug Product Portfolios and Specifications
Table 81. BeiGene, Ltd. Leiomyosarcoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 82. BeiGene, Ltd. Main Business
Table 83. BeiGene, Ltd. Latest Developments
Table 84. Cell Medica Limited Basic Information, Leiomyosarcoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 85. Cell Medica Limited Leiomyosarcoma Drug Product Portfolios and Specifications
Table 86. Cell Medica Limited Leiomyosarcoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 87. Cell Medica Limited Main Business
Table 88. Cell Medica Limited Latest Developments
Table 89. Karyopharm Therapeutics, Inc. Basic Information, Leiomyosarcoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 90. Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Product Portfolios and Specifications
Table 91. Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 92. Karyopharm Therapeutics, Inc. Main Business
Table 93. Karyopharm Therapeutics, Inc. Latest Developments
Table 94. Merck & Co., Inc. Basic Information, Leiomyosarcoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 95. Merck & Co., Inc. Leiomyosarcoma Drug Product Portfolios and Specifications
Table 96. Merck & Co., Inc. Leiomyosarcoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 97. Merck & Co., Inc. Main Business
Table 98. Merck & Co., Inc. Latest Developments
Table 99. Mirati Therapeutics Inc. Basic Information, Leiomyosarcoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 100. Mirati Therapeutics Inc. Leiomyosarcoma Drug Product Portfolios and Specifications
Table 101. Mirati Therapeutics Inc. Leiomyosarcoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 102. Mirati Therapeutics Inc. Main Business
Table 103. Mirati Therapeutics Inc. Latest Developments
Table 104. Novartis AG Basic Information, Leiomyosarcoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 105. Novartis AG Leiomyosarcoma Drug Product Portfolios and Specifications
Table 106. Novartis AG Leiomyosarcoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 107. Novartis AG Main Business
Table 108. Novartis AG Latest Developments
Table 109. Vicore Pharma AB Basic Information, Leiomyosarcoma Drug Manufacturing Base, Sales Area and Its Competitors
Table 110. Vicore Pharma AB Leiomyosarcoma Drug Product Portfolios and Specifications
Table 111. Vicore Pharma AB Leiomyosarcoma Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 112. Vicore Pharma AB Main Business
Table 113. Vicore Pharma AB Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Leiomyosarcoma Drug
Figure 2. Leiomyosarcoma Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Leiomyosarcoma Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Leiomyosarcoma Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Leiomyosarcoma Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Leiomyosarcoma Drug Sales Market Share by Country/Region (2024)
Figure 10. Leiomyosarcoma Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of AL-3818
Figure 12. Product Picture of BGB-290
Figure 13. Product Picture of C-21
Figure 14. Product Picture of Others
Figure 15. Global Leiomyosarcoma Drug Sales Market Share by Type in 2025
Figure 16. Global Leiomyosarcoma Drug Revenue Market Share by Type (2020-2025)
Figure 17. Leiomyosarcoma Drug Consumed in Clinic
Figure 18. Global Leiomyosarcoma Drug Market: Clinic (2020-2025) & (K Pcs)
Figure 19. Leiomyosarcoma Drug Consumed in Hospital
Figure 20. Global Leiomyosarcoma Drug Market: Hospital (2020-2025) & (K Pcs)
Figure 21. Leiomyosarcoma Drug Consumed in Others
Figure 22. Global Leiomyosarcoma Drug Market: Others (2020-2025) & (K Pcs)
Figure 23. Global Leiomyosarcoma Drug Sale Market Share by Application (2024)
Figure 24. Global Leiomyosarcoma Drug Revenue Market Share by Application in 2025
Figure 25. Leiomyosarcoma Drug Sales by Company in 2025 (K Pcs)
Figure 26. Global Leiomyosarcoma Drug Sales Market Share by Company in 2025
Figure 27. Leiomyosarcoma Drug Revenue by Company in 2025 ($ millions)
Figure 28. Global Leiomyosarcoma Drug Revenue Market Share by Company in 2025
Figure 29. Global Leiomyosarcoma Drug Sales Market Share by Geographic Region (2020-2025)
Figure 30. Global Leiomyosarcoma Drug Revenue Market Share by Geographic Region in 2025
Figure 31. Americas Leiomyosarcoma Drug Sales 2020-2025 (K Pcs)
Figure 32. Americas Leiomyosarcoma Drug Revenue 2020-2025 ($ millions)
Figure 33. APAC Leiomyosarcoma Drug Sales 2020-2025 (K Pcs)
Figure 34. APAC Leiomyosarcoma Drug Revenue 2020-2025 ($ millions)
Figure 35. Europe Leiomyosarcoma Drug Sales 2020-2025 (K Pcs)
Figure 36. Europe Leiomyosarcoma Drug Revenue 2020-2025 ($ millions)
Figure 37. Middle East & Africa Leiomyosarcoma Drug Sales 2020-2025 (K Pcs)
Figure 38. Middle East & Africa Leiomyosarcoma Drug Revenue 2020-2025 ($ millions)
Figure 39. Americas Leiomyosarcoma Drug Sales Market Share by Country in 2025
Figure 40. Americas Leiomyosarcoma Drug Revenue Market Share by Country (2020-2025)
Figure 41. Americas Leiomyosarcoma Drug Sales Market Share by Type (2020-2025)
Figure 42. Americas Leiomyosarcoma Drug Sales Market Share by Application (2020-2025)
Figure 43. United States Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 44. Canada Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 45. Mexico Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Brazil Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. APAC Leiomyosarcoma Drug Sales Market Share by Region in 2025
Figure 48. APAC Leiomyosarcoma Drug Revenue Market Share by Region (2020-2025)
Figure 49. APAC Leiomyosarcoma Drug Sales Market Share by Type (2020-2025)
Figure 50. APAC Leiomyosarcoma Drug Sales Market Share by Application (2020-2025)
Figure 51. China Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 52. Japan Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 53. South Korea Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. Southeast Asia Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. India Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Australia Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. China Taiwan Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. Europe Leiomyosarcoma Drug Sales Market Share by Country in 2025
Figure 59. Europe Leiomyosarcoma Drug Revenue Market Share by Country (2020-2025)
Figure 60. Europe Leiomyosarcoma Drug Sales Market Share by Type (2020-2025)
Figure 61. Europe Leiomyosarcoma Drug Sales Market Share by Application (2020-2025)
Figure 62. Germany Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 63. France Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 64. UK Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. Italy Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. Russia Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Middle East & Africa Leiomyosarcoma Drug Sales Market Share by Country (2020-2025)
Figure 68. Middle East & Africa Leiomyosarcoma Drug Sales Market Share by Type (2020-2025)
Figure 69. Middle East & Africa Leiomyosarcoma Drug Sales Market Share by Application (2020-2025)
Figure 70. Egypt Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 71. South Africa Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 72. Israel Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 73. Turkey Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. GCC Countries Leiomyosarcoma Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Leiomyosarcoma Drug in 2025
Figure 76. Manufacturing Process Analysis of Leiomyosarcoma Drug
Figure 77. Industry Chain Structure of Leiomyosarcoma Drug
Figure 78. Channels of Distribution
Figure 79. Global Leiomyosarcoma Drug Sales Market Forecast by Region (2026-2031)
Figure 80. Global Leiomyosarcoma Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 81. Global Leiomyosarcoma Drug Sales Market Share Forecast by Type (2026-2031)
Figure 82. Global Leiomyosarcoma Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 83. Global Leiomyosarcoma Drug Sales Market Share Forecast by Application (2026-2031)
Figure 84. Global Leiomyosarcoma Drug Revenue Market Share Forecast by Application (2026-2031)